ArticleMedicine2026
From compounds to mechanism: unveiling the therapeutic action of Rudijinniuding on herpes zoster via integrated UPLC-Q/TOF-MS, network pharmacology, and molecular dynamics analyses.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Rudijinniuding (RDJND), a proprietary formulation developed by Guangdong Provincial Hospital of Chinese Medicine, has demonstrated favorable anti-inflammatory and analgesic effects when applied in herpes zoster (HZ). However, its specific bioactive composition and underlying mechanisms remain unclear. The major constituents of RDJND were identified using ultra‑performance liquid chromatography with quadrupole/time‑of‑flight mass spectrometry. Network pharmacology was employed to screen for potential targets against HZ. Furthermore, molecular docking and molecular dynamics simulations were conducted to systematically elucidate the mechanism of action of RDJND against HZ. A total of 35 components were identified in RDJND, primarily alkaloids, phenolic acids, flavonoids, and coumarins. Network pharmacology analysis suggested that the effects of RDJND on HZ might involve the regulation of the phosphoinositide 3‑kinase/protein kinase B and mitogen‑activated protein kinase signaling pathways, as well as biological responses such as oxidative stress and responses to bacteria-derived molecules. Molecular docking and dynamics simulations further confirmed that the relevant complexes exhibited strong binding affinity and stability. This study clarified the bioactive composition of RDJND and its comprehensive pharmacological effects in the treatment of HZ through multi-target and multi-pathway mechanisms. These findings provide a theoretical basis for the clinical application of RDJND in HZ treatment and lay the groundwork for subsequent research and development efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.